TherapeuticsMD (TherapeuticsMD) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD 5-Year Dividend Growth Rate?

TherapeuticsMD's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

TherapeuticsMD's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, TherapeuticsMD's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of TherapeuticsMD's 5-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TherapeuticsMD's 5-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's 5-Year Dividend Growth Rate falls into.

TherapeuticsMD 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

TherapeuticsMD (NAS:TXMD) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

TherapeuticsMD's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.14
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TherapeuticsMD 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

TherapeuticsMD (TherapeuticsMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

29TA:Germany

Address

951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431

Website

https://www.therapeuticsmd.com

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

Executives

Marlan D Walker	officer: General Counsel	951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler	officer: Principal Financial Officer	1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan	officer: CAO and VP of Finance	6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman	officer: Chief Business Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts	director	C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro	director
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing	director	9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C.	director	33219 FOREST WEST DRIVE, MAGNOLIA TX 77354